Imclone

Some articles on imclone:

Marthastewart - Stock Trading Case and Conviction
... by selling all 3,928 shares of her ImClone Systems stock on December 27, 2001, after receiving material, nonpublic information from Peter Bacanovic, who was Stewart's broker at Merrill Lynch ... Notably, on June 25, 2002, CBS anchor Jane Clayson grilled Stewart on the air about ImClone during her regular segment on The Early Show ... showed that Bacanovic had ordered his assistant to tell Stewart that the CEO of ImClone, Samuel D ...
Im Clone Stock Trading Case - History
... ImClone's stock price dropped sharply at the end of 2001 when its drug Erbitux, an experimental monoclonal antibody, failed to get the expected Food and Drug Administration (FDA) approval ... ImClone's founder, Samuel D ... after it emerged that Bacanovic tipped her off that ImClone was about to drop ...
ImClone Systems - Takeover Offer From Bristol-Myers Squibb, and Subsequent Bidding Showdown
... On July 31, 2008, Bristol-Myers Squibb offered to take over ImClone for $60 a share cash ... The offer was made by letter addressed to ImClone's chairman of the board, Carl Icahn ... On September 10, 2008, An undisclosed company and CEO offered to take over ImClone for $70 a share, financing approach was not disclosed ...
Samuel D. Waksal - Education and Early Career
... Undaunted, Waksal founded ImClone in 1984 ... The drug's clinical success caused ImClone's stock to jump as high as $70 a share ... Those plans hit a snag, however, when the Food and Drug Administration turned down ImClone's application due to concerns about the structure of the clinical trials ...
White-collar Crime - Relationship To Other Types of Crime - Corporate Crime
... One well-known insider trading case in the United States is the ImClone stock trading case. 2001, top-level executives sold their shares in ImClone Systems, a pharmaceutical company that manufactured an anti-cancer drug ... as well as Martha Stewart, a friend of ImClone's former chief executive who had also sold her shares at the same time ...